A practical reference on thymalfasin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-12 and is reviewed periodically as new material appears.
在信号层面,Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示,它能激活髓样分化因子88依赖的通路,进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答,有助于细胞免疫。然而,具体受体和结合位点尚未完全确定,不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善,但临床终点获益在不同研究中并不一致。系统综述指出,研究间在人群、剂量和联合方案上差异较大,难以汇总结论。因此,Tα1的确切临床地位仍属开放问题,需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| 主要靶细胞 | T细胞、树突状细胞 | 也影响NK细胞 |
| 信号通路 | TLR/MyD88/NF-κB | 部分实验模型 |
| 细胞因子偏向 | Th1型 | 增加IL-2、IFN-γ |
| 给药途径 | 皮下注射 | 临床常用 |
| 半衰期 | 约2小时 | 血浆中较短 |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
The result of this extensive procedure was still not a pure protein, but it produced a limited number of bands by SDS-PAGE, and one band of 46 kilodaltons was found to correlate in intensity with the enzymatic activity. This band was cut from the gel and digested with trypsin, and peptides from it were separated from one another by reverse phase high performance liquid chromatography. The resulting fragments were then microsequenced by an automated Edman degradation. Three corresponded to vimentin, an intermediate filament protein of 56 kDa believed to be a contaminant, and the other two matched the cDNA clone subsequently identified as NAPE-PLD. Once this clue had been obtained, the identification could be confirmed by a less onerous procedure: Overexpression of the putative NAPE-PLD cDNA in COS-7 cells yielded a strong NAPE-PLD enzymatic activity, whose characteristics were shown to be similar to those of the original heart extract.
This remained Knoxville's style of government until the early 20th century, though the city's charter was amended in 1838 to allow for popular election of mayor as well. In January 1816, Knoxville's newly elected Board of Aldermen chose Judge Thomas Emmerson (1773–1837) as the city's first mayor. With the exceptions of the years 1802, 1807, 1811 and 1812, Knoxville remained the capital of Tennessee until 1817 when the state legislature was moved to Murfreesboro.
== History == EFLM was created from the merger of two precursor organisations, The Federation of European Societies of Clinical Chemistry (FESCC), (a European representative of the International Federation of Clinical Chemistry and Laboratory Medicine, IFCC) and the European Community Confederation of Clinical Chemistry (EC4) at the EuroMedlab meeting in Amsterdam in 2007. Both precursor organizations arose in the 1970s. The increasing overlap between the European Union, represented by EC4 and FESCC, representing geographical Europe, meant that merger was appropriate.
Sources: en.wikipedia.org
Porcine All three previously mentioned types of retinol-binding proteins (RBP, CRBP, CRABP) have been identified within the porcine placenta during pregnancy via immunohistochemistry. As previously mentioned, retinol and retinoic acid are modulators of gene expression and are necessary for the proper development and growth of a conceptus. Porcine exhibit a diffuse type placenta that has areolar-gland subunits which allows for transport of larger molecules between dam and fetus. RBP and CRBP have been identified in the endometrial glands and areolar trophoblasts, suggesting that RBP is crucial in transport of retinol from the gland to the trophectoderm of the conceptus. RBP expression has also been identified within the yolk sac, myometrium, oviduct, and numerous other fetal tissues.
== Clinical Research and Clinical Trials == Clinical research at the Barshop Institute is dedicated to translating discoveries in the biology of aging into interventions that improve healthspan, preserve functional independence, and prevent or delay the onset of chronic age-related diseases. The Institute maintains a robust clinical research infrastructure that supports Phase I–IV clinical trials, investigator-initiated studies, and multicenter collaborations spanning basic translational research through large-scale clinical investigations. Investigators conduct studies involving older adults across a broad spectrum of aging-related conditions, including frailty, sarcopenia, metabolic dysfunction, obesity, type 2 diabetes, cardiovascular disease, Alzheimer's disease and related dementias, mobility impairment, osteoporosis, and other chronic conditions that disproportionately affect aging populations. Clinical trials evaluate novel therapeutics, lifestyle interventions, nutritional strategies, exercise programs, and repurposed medications designed to improve physical function, cognitive health, metabolic resilience, and overall quality of life. The Institute's clinical research enterprise is strengthened through close collaboration among physician-scientists, basic scientists, biostatisticians, epidemiologists, rehabilitation specialists, nutrition experts, and clinical research professionals.
In enzymology, creatinase (EC 3.5.3.3), also known as creatine amidinohydrolase, is classified as a hydrolase enzyme, acting on carbon-nitrogen bonds in linear amidines. Specifically, this enzyme breaks the amidino C-N bond in creatine, producing sarcosine and urea. Creatinase activity has been described in several bacteria species, most notably Pseudomonas putida, where the enzyme plays a key role in the metabolism of creatine as a nitrogen and carbon source.
At the end of its 2013 fiscal year, Burger King was the second largest chain of hamburger fast food restaurants in terms of global locations, behind industry bellwether McDonald's, which had 32,400 locations. At the end of 2014, Burger King ranked fourth among US food chains in terms of US sales, behind McDonald's, Starbucks, and Subway. Burger King now has over 12,000 stores worldwide. In January 2024, Restaurant Brands International, the owner of the brand, announced it would purchase the largest franchisee of the chain, Carrols Restaurant Group, for around $1 billion. At the time of the announcement, Carrols had 1,022 Burger King locations (along with 60 Popeyes locations). The goal was to remodel 600 of the restaurants, then sell them back to franchisees over five to seven years. The move represented a departure from the existing model of largely franchising locations.
Sources: en.wikipedia.org
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。
目前认为它可能通过Toll样受体等模式识别受体传递信号,但精确的受体身份和结合机制尚未完全阐明。
不同试验在患者选择、给药方案、联合治疗和终点定义上差异很大。这些异质性使得跨研究比较困难,结论难以统一。
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.